

The research commercialisation office of the University of Oxford, previously called **Isis Innovation**, has been renamed **Oxford University Innovation**

All documents and other materials will be updated accordingly. In the meantime the remaining content of this Isis Innovation document is still valid.

URLs beginning <u>www.isis-innovation.com/</u>... are automatically redirected to our new domain, <u>www.innovation.ox.ac.uk/</u>...

Phone numbers and email addresses for individual members of staff are unchanged

Email : enquiries@innovation.ox.ac.uk



Alzheimer's disease

big problem, Big Data, big solution



The problem

- More than 800,000 people with dementia
- Costs more than £20 billion per annum
- \$2 billion trials failure





- Diversify target development
- Trials in prodromal or preclinical disease
- Rapid trials with early read-outs



Big data characteristics



volume

variety

velocity

complexity




Collaboration for translational research in dementia

Alzheimer's Research UK Oxford Drug Development Institute

Wellcome Trust Strategic awards:

Target Enabling Packages

Neuroinflammation



Deep and Frequent Phenotyping cohort



IMI-EPAD

European Prevention of Alzheimer's disease

Readiness register, cohort and Early Phase Trials

Pre-competitive data driven drug development Pre-competitive cohort repurposing for experimental medicine Pre-competitive reutilisation of research and real-world data Pre-competitive data driven PoC/PhII




Collaboration for translational research in dementia

Alzheimer's Research UK Oxford Drug Development Institute

Wellcome Trust Strategic awards:

Target Enabling Packages

Neuroinflammation



Deep and Frequent Phenotyping cohort

(n=10k)



IMI-EPAD

European Prevention of Alzheimer's disease

Readiness register, cohort and Early Phase Trials


Pre-competitive data driven drug development Pre-competitive cohort repurposing for experimental medicine Pre-competitive reutilisation of research and real-world data

Pre-competitive data driven PoC/PhII





- Diversify target development
- Trials in prodromal or preclinical disease
- Rapid trials with early read-outs





UK Biobank for Dementia Research

- 500,000 participants; baseline assessments 2005-8
- Web-based questionnaires for additional exposures and outcomes (cognition, mental health, occupation..)
- Multimodal imaging in 100,000 brain, cardiac and body fat MRI; bone & joint DEXA; 3D carotid ultrasound
- Repeat Neuroimaging, cognition and sampling in 20,000
- Genotyping of all participants (820,000 SNPs)
- Connectivity to EMRs for mental health





Deep and Frequent Phenotyping

Deep phenotyping

- PET
- CSF repeated measures
- MRI serial imaging with noise reduction strateg

 $A\beta$ and tau tracers

- Electrophysiology EEG and MEG
- Peripheral markers noise reduction, change measurement
- Cognitive markers computerised batteries, web testing integration
- Novel markers *retinal imaging, quantitative gait measures*

Frequent phenotyping

• Test the limits of acceptability

monthly, bi-monthly





Use of EMRs for research



- SLaM CRIS
 - South London and Maudsley NHS BRC implementation
 - D-CRIS
 - Cambridge & Peterborough, Oxford Health,
 West London, Camden and Islington
 - 1 million plus patients
- UK-CRIS
 - 10 site extension
 - Connectivity to UK BioBank
- Mike Denis and Simon Lovestone




CRIS – core functionality

01

190 200

🛏 🔁 📜 0 🛼 🔮 🗷 🖉 🖉





GATE – Text Parsing


FAST enables information retrieval, i.e. search and retrieval by matching against user defined strings;

GATE enables information extraction, i.e. extracts 'meaning' (structure) from free text context



GATE use case:

extract MMSE score and date from free text






EHR-data re-use for research

(Cholinesterase inhibitors and Alzheimer's disease)

- Phase IV of ACHel
 - > 2500 patient years of therapy> 8 fold dataset compared to Cochrane
- Costs and effectiveness precompetitive collaboration with pharma Text mining derivation of service utilisation and costs
- Predictors of response Biomarkers and clinical



Data from Robert Stewart




Collaboration for translational research in dementia

Alzheimer's Research UK Oxford Drug Development Institute

Wellcome Trust Strategic awards:

Target Enabling Packages

Neuroinflammation



Deep and Frequent Phenotyping cohort

(n=10k)



IMI-EPAD

European Prevention of Alzheimer's disease


Readiness register, cohort and Early Phase Trials

Pre-competitive data driven drug development Pre-competitive cohort repurposing for experimental medicine Pre-competitive reutilisation of research and real-world data

Pre-competitive data driven PoC/PhII




European Medical Information Framework





Private Remote Research Environments



Remote Research Environment



Available EMR data sources – EMIF-Platform

Database name	total (cumulative) # of subjects	# of active patients in January 2012
Aarhus (DK)	2.3 million	1.8 million
Regional DB Tuscany (IT)	4.8 million	3.8 millions
GePaRD (DE)	17 million	12.655.616 (Jan 2007)
THIN (UK)	> 11 million	3.8 million (Sept 2012)
IPCI (NL)	2.9 million	1.6 million
Health Search (IT)	> 2 million	930,000
Pedianet (IT) (0 to 14 years)	400,000	150,000
Pharmo (NL)	> 7 million	5 million
Birth Cohort (UK)	1,184	960
Cardiovasc. Interv. Registry (UK)	460,000	3,000
Salford Diabetes registry (UK) TBC	12,000	12,000
IMASIS (ES)		
EGCUT (ES)	52,000	NA
TOTAL	~ 48 million	~ 17 million



Repurposing from real world data

- Do diseases of inflammation alter risk of AD ?
- Do anti-inflammatory drugs alter risk of AD ?
- Are genetic variants related to inflammatory pathways modulators of risk ?



Big Data and the dementia challenge ?



volume



velocity

complexity

Big data solution

- Add volume : 50m records
- Add variety : pan-omic, structural and functional imaging etc
- Add complexity : deep and broad, coded and narrative



Big Data and the dementia challenge ?







complexity

volume

variety

velocity







Mike Denis; CIO Oxford Academic Health Sciences Network



With thanks to....

- > 50 executive members
- > 150 principal investigators
- > 500 scientists
- >1500 collaborators
- > 50,000 volunteers
- > 50,000,000 individuals contributing data
- > 200,000,000 euros from funders






Collaboration for translational research in dementia

Alzheimer's **Research UK Oxford** Drug Development Institute

Wellcome Trust Strategic awards:

Target Enabling Packages

Neuroinflammation



and *very* many others......